Massively parallel pyrosequencing allows sensitive deep sequencing to detect molecular aberrations. Thus far, data are limited on the technical performance in a clinical diagnostic setting. Here, we investigated as an international consortium the robustness, precision and reproducibility of amplicon nextgeneration deep sequencing across 10 laboratories in eight countries. In a cohort of 18 chronic myelomonocytic leukemia patients, mutational analyses were performed on TET2, a frequently mutated gene in myeloproliferative neoplasms. Additionally, hotspot regions of CBL and KRAS were investigated. The study was executed using GS FLX sequencing instruments and the small volume 454 Life Sciences Titanium emulsion PCR setup. We report a high concordance in mutation detection across all laboratories, including a robust detection of novel variants, which were undetected by standard Sanger sequencing. The sensitivity to detect low-level variants present with as low as 1-2% frequency, compared with the 20% threshold for Sanger-based sequencing is increased. Together with the output of high-quality long reads and fast run time, we demonstrate the utility of deep sequencing in clinical applications. In conclusion, this multicenter analysis demonstrated that amplicon-based deep sequencing is technically feasible, achieves high concordance across multiple laboratories and allows a broad and in-depth molecular characterization of cancer specimens with high diagnostic sensitivity.
Introduction
Massively parallel pyrosequencing in picoliter-sized wells is an innovative next-generation DNA sequencing (NGS) technique that enables highly-sensitive deep sequencing to detect molecular aberrations. 1, 2 It has become apparent that NGS platforms will have practical applications in clinical diagnostics and applications, such as detection of EGFR mutations in lung adenocarcinoma, 3 characterizing RAS and methylation pathway alterations in myeloproliferative diseases and myeloid leukemias, [4] [5] [6] [7] or high-resolution, high-throughput human leukocyte antigen genotyping have been developed. 8, 9 Thus far, limited data are available on the technical performance of amplicon deep sequencing in a clinical diagnostic setting. Here, we reportFas an international consortiumFthe results of our investigation concerning the robustness, precision and reproducibility of amplicon NGS across 10 laboratories from eight countries. In particular, we focused on the utility of amplicon deepsequencing assays in characterizing myeloid neoplasms, where the number of molecular markers applied for disease classification, patient stratification and individualized monitoring of minimal residual disease is constantly increasing. Each participating laboratory had received blinded aliquots of 18 centrally collected patient DNA samples to be processed. This study used preconfigured 96-well plates containing lyophilized primer pairs targeting genes of interest in hematological malignancies. As a first candidate gene, we selected TET2, a frequently mutated gene in adult myeloproliferative neoplasms. 10 Additional primer pairs were amplifying hotspot regions of CBL and KRAS. 11, 12 To execute our study, we used the small volume 454 Life Sciences Titanium emulsion PCR setup (454 Life Sciences, Branford, CT, USA). 13, 14 Patients and methods
Patients and study design
This study included 18 chronic myelomonocytic leukemia patient samples, sent to the MLL Munich Leukemia Laboratory for diagnostic assessment between October 2005 and April 2008. Bone marrow or peripheral blood mononuclear cells were enriched for molecular analyses using a Ficoll density gradient. Sanger sequencing was performed using BigDye chemistry (Applied Biosystems, Weiterstadt, Germany) and by applying the same primer pairs as for NGS amplicon generation. The study design adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review board before its initiation. Each of the 10 participating laboratories received anonymized aliquots containing 1.6 mg of genomic DNA for each of the 18 study samples, diluted to 20 ng/ml, to be processed for the generation of PCR amplicons suitable for deep sequencing. The 10 laboratories had varying levels of experience in amplicon deep sequencing on the GS FLX platform.
Amplicon preparation
In total, 31 primer pairs including a 10-base molecular identifier barcode sequence (MID) were designed and evaluated (Supplementary Tables 1-3) . Each laboratory received preconfigured 96-well primer plates. Each primer plate contained 31 primer pairs and one negative control well for three distinct MIDs (Supplementary Figure 1a) . The molecular barcodes used were MID-1 (ACGAGTGCGT), MID-2 (ACGCTCGACA) and MID-4 (AGCACTGTAG). All coding exons of TET2 were represented by 27 amplicons. In addition, two primer pairs were amplifying hotspot regions to characterize the RING finger domain and linker sequence for CBL and two additional amplicons were covering KRAS exons 2 and 3.
A total of 31 amplicon preparations across 18 samples, that is, 558 individual PCR reactions, were locally performed at each laboratory, using the FastStart High Fidelity PCR System kit (Roche Applied Science, Penzberg, Germany). After all 18 samples were prepared in six separate 96-well plates, each PCR product was individually purified using Agencourt AMPure XP beads (Beckman Coulter, Krefeld, Germany) and quantified using the Quant-iT PicoGreen dsDNA kit (Invitrogen, Carlsbad, CA, USA). Corresponding patient-specific amplicon pools were generated by combining 100 ng of each of the 31 amplicons in an equimolar ratio for each patient sample. Further, six individual lane pools were generated by combining equimolar amounts of MID-1, MID-2 and MID-4 for each lane. The concentration of individual lane pools was assessed using the Quant-iT PicoGreen dsDNA kit (Invitrogen) and each lane pool then was adjusted to 1 Â 10 9 molecules per ml (Supplementary Figure 1b) . Information on primer sequences and the respective cycler protocol are given online (Supplementary Table 4 ).
Next-generation deep sequencing
The six final lane pools then were prepared for the emulsion PCR step. First, the pools were diluted to a concentration of 4 Â 10 6 molecules per ml (Supplementary Figure 2) . Second, the libraries were processed using the GS FLX Titanium Series Lib-A SV method (Roche Applied Science). Forward (A beads) and reverse (B beads) reactions were carried out using 2 000 000 beads per emulsion oil tube. The copy per bead ratio used was 2.1. The amplification reaction, breaking of the emulsions and enrichment of beads carrying amplified DNA was performed using the workflow as recommended by the manufacturer. However, A beads and B beads were separately processed during breaking and enrichment processes. Finally, three patients each were loaded per lane on an 8-lane PicoTiterPlate (PTP) on the Genome Sequencer FLX System instrument (Roche Applied Science). Samples of this study occupied lane 1 through 6 on a PTP (Supplementary Figure 2) . Additional information on the NGS sample preparation steps, bead enrichment success rate and bead amount loaded per PTP lane is provided online.
Data analysis and detection of variants
All data were generated using the GS FLX Sequencer Instrument software version 2.3 (Roche Applied Science). Image processing and amplicon pipeline analysis was performed using default settings of the GS RunBrowser software version 2.3 (Roche Applied Science). Sequence alignment and variant detection was performed using the GS Amplicon Variant Analyzer software version 2.3 (Roche Applied Science). The results were further processed and visualized in R/Bioconductor using the package R453Plus1Toolbox (version 1.0.1) and the Sequence Pilot software version 3.4.0 (JSI Medical Systems, Kippenheim, Germany). 15 For the detection of variants, filters were set to display sequence variances occurring in more than 1% of bidirectional reads per amplicon in at least one patient. Alterations and single nucleotide polymorphisms (SNPs) according to dbSNP build 131 within introns were not scored. 16 
Statistical analysis
To test if the coverage output of all laboratories was equal we applied a Friedman rank sum test for unreplicated blocked data. 17 A block was specified as the combination of an amplicon and a sample, thus we obtained 558 blocks. For a P-value smaller than a ¼ 0.05, we could reject the null hypotheses that the coverages of all laboratories are equal.
The relative frequency h il of variant i measured at laboratory l is defined as the number of reads carrying the variation, divided by the number of all reads spanning the position of the variant. To assess the dispersion of the relative frequencies across the laboratories, the standard deviation of h il was estimated under the assumption
For each pair of laboratories k and l, the paired t-test for equivalence was used to test the hypothesis H kl : d kl /s kl pÀ0.5 or d kl /s kl X0.5 vs K kl : À0.5od kl /s kl o0.5. When all null hypotheses for the pairwise comparisons were rejected at a nominal level a ¼ 0.05, it follows from the intersection union principle that also the combined hypothesis H ¼ U 1pkolp10 H kl can be rejected at a ¼ 0.05. 18 Bland-Altman plots were used to visualize the differences D ikl between laboratories k and l. 19 The estimated d kl is represented by a red solid line. The red dashed lines indicate the interval d kl ±1.96 s kl , in which 95% of the differences are expected to lie.
Variants with a median relative frequency X20%, over all 10 centers in the forward reads, and a median relative frequency X20% in the reverse reads were considered as most likely variants. Overall, 80 most likely variants were detected and we used these sequence alterations for the plots and calculations presented in the manuscript, unless stated otherwise. Low-level variants were defined in an analogous manner as variants with a median relative frequency between 1 and 20%. We detected 14 low-level variants.
Results

Sample characteristics
A cohort of 18 chronic myelomonocytic leukemia patient samples were centrally collected by the MLL Munich Leukemia Laboratory and characterized by conventional Sanger sequencing for mutations in TET2, CBL and KRAS. In this selected cohort, 31 distinct mutations in TET2, 7 mutations in CBL and 3 mutations in KRAS, respectively, were detected by Sanger sequencing at the collecting site. Additionally, eight distinct SNPs and one silent mutation were detected in TET2. Table 1 provides a summary of the patient characteristics and their overall variant profile.
Sequencing coverage
Upon receiving the blinded DNA specimens, each laboratory independently performed the sample preparation procedure and sequencing protocol, using the small volume Titanium amplicon workflow. Overall, a median of 430 402 high-quality sequencing reads was generated across each of the 10 participating laboratories for all 31 PCR amplicons and 18 study samples. The number of obtained sequencing reads ranged from 140 399 (laboratory 2) to 601 776 (laboratory 1). For each of the 31 amplicons, the distribution of generated reads is represented by box-and-whisker plots in Figure 1a . The median coverage per amplicon was 689-fold, ranging from 541 to 872-fold. Figure 1b demonstrates that both the forward and reverse strands were successfully and homogeneously sequenced. Dropouts of single amplicons with no coverage were observed in 6/10 laboratories in 71 of 5580 PCR products (1.3%), respectively. Further, comparable amounts of amplicon reads were generated for all MIDs (Figure 1c) . A median of 23 820 (21 796, 24 637) reads was observed for samples tagged with MID-1 (MID-2, MID-4). As demonstrated in Supplementary Figure 3 , laboratories with experience in 454 amplicon deep sequencing, and in particular those applying automated solutions for amplicon purification, did generate a more homogeneous coverage. Figure 2 indicates that laboratory 1 has obtained a higher coverage than all other laboratories, whereas laboratories 2 and 9 obtained less reads. The differences between all ten laboratories were highly significant, as the P-value for the Friedman rank sum test was smaller than 0.001. Additional laboratory-specific comparisons are provided online (Supplementary Figure 4) .
Detection of variants in comparison to Sanger sequencing
After alignment of the obtained sequences against the reference genome, a total of 66 variants were observed across 24 amplicons. However, due to the design of overlapping PCR amplicons in the larger TET2 exons 3, 10 and 11, 3 variants were observed in two amplicons each. In detail, Q440X was observed in amplicons E03.05 and E03.06 (sample #5); C1464X was observed in amplicons E10.01 and E10.02 (sample #13); and I1762V was observed in amplicons E11.03 and E11.04 (12 cases; Supplementary Data Spreadsheet 1). Thus, the total number of variants available for statistical analyses increased to 80. These 80 variants were corresponding to the initial 41 distinct mutations, nine distinct SNPs and one silent mutation (Table 1) .
For comparison analyses against data from Sanger sequencing, a given variant was scored if the median relative frequency of reads harboring the variant was X20%, for forward reads as well as reverse reads. This threshold was in line with the Sanger sequencing detection limit. In comparison to variant data available from Sanger sequencing, 454 amplicon deep sequencing detected all mutations and SNPs that were previously known. However, for three TET2 variants, that is, N1018KfsX11, E1207X and I1762V, not all data were available for statistical assessment because of rare events of amplicon dropouts at single laboratories (Supplementary Data Spreadsheet 1). In 61/ 66 variant comparisons, all 10 laboratories consistently detected the variant with both forward and reverse reads X20% (Supplementary Data Spreadsheet 1). In three TET2 variantsFW1003X and two times in I1762VFthe mutational load was o20% in one of the centers in at least one sequencing direction. For two KRAS variants detected in sample #10, that is, L19F and T20S, the mutational burden was o20% in 7/10 laboratories in at least one sequencing direction (Supplementary Data Spreadsheet 1).
Two exemplary variants in TET2, that is, G1154D and N1504SfsX61, are highlighted in Figure 3 , and indicate the mutation percentage and coverage distribution across all laboratories. Figure 3a shows the G1154D mutation (G4A exchange), which was detected in 37% of the 800 reads generated by center 7. The N1504SfsX61 mutation, a 13-bp deletion alteration, was detected in 38% of the 857 reads in laboratory 7 (Figure 3b ). In Figures 3c and d , the same G1154D and N1504SfsX61 variants are given across all participating laboratories. The percentage of mutated reads was ranging from 30.5 to 37.4% for G1154D (median: 35.7%) and 35.1 to 43.7% for N1504SfsX61 (median: 38.6%). The respective coverage that was obtained in the individual laboratories was ranging from 242 to 1360 reads for G1154D (median: 643) and 331 to 1103 reads for N1504SfsX61 (median: 523). It thus can be strikingly observed that the number of reads was differing between the individual centers, yet the detected mutational burden of both variants was comparable across all laboratories. Moreover, amplicon deep sequencing also allowed delineating separate subclones in cases with double mutations, where both alterations were harbored in the same amplicon sequence (Supplementary Figure 5) . Figure 4a shows the distributions of median-centered relative variant frequencies across all laboratories. Each relative frequency of a detected variant per laboratory was subtracted by the median relative frequency of this variant across all laboratories. The homogeneity of these boxes suggested that the laboratories did not differ in their proportions of detected variants, despite of the underlying discrepancies in sequencing read coverage (Figure 2) . In more detail, Bland-Altman analyses were performed to investigate the differences in the percentages of reads detecting a variant for systematic errors between any two centers. For example, as demonstrated in Figure 4b , each dot in the comparison of center 7 and center 8 represents one of the 80 most likely variants. The mean relative frequency of a variant is plotted against the difference of the relative frequencies measured by the two laboratories. The 95% limits of agreement, given as red dashed lines, ranged from À4.5 to 5.5% in this comparison, with a mean difference of 0.5%. More detailed information for all 45 pairwise comparisons of the centers is presented in Supplementary Data Spreadsheet 1 and in Supplementary Figure 6 in the online data supplement. In summary, no considerable bias between any two centers was observed. The mean of differences between centers ranged from À1.3 to 1.2%.
Statistical assessment of reproducibility of sequencing results
On the basis of paired t-tests for equivalence across all 80 individual variants, with equivalence limits for the standardized expected differences between two centers of ±e (e ¼ 0.5), the null hypothesis of dissimilar measurements was rejected for all pairs of centers (a ¼ 0.05). The estimated standard deviation of the measurements across the centers was 3.0% (95% confidence interval: [2.9%, 3.2%]), demonstrating the high precision of 454 deep sequencing to detect molecular mutations.
Deep sequencing analysis
In the following, we took advantage of the high sensitivity of deep sequencing. Nine cases demonstrated 14 distinct low-level variants with frequencies below the Sanger sequencing detection limit of 20% (median values ranging from 1.6 to 11.6%). As listed in Table 2 , these mutations were observed in TET2 (n ¼ 2), CBL (n ¼ 8) and KRAS (n ¼ 4). A total of 6/14 of these low-level alterations were consistently detected in all laboratories. Additionally, one CBL mutation (R420L) and one KRAS mutation (G12S) with o3% median frequency were detected only in 9/10 centers. In both instances, the mutated amplicon had not been sequenced in laboratory 6, due to a dropout at the stage of either 
Figure 1 Coverage distribution across amplicons and MIDs. (a) For each of the 31 amplicons (x axis), the distribution of generated reads is represented (y axis). Box-and-whisker plots summarize the corresponding overall coverage across all laboratories and (b) according to forward (A reads) and reverse (B reads) directions. (c) Distribution of the number of forward and reverse reads across all laboratories separated by the molecular barcode (MID-1, MID-2 or MID-4)
. Note: three amplicons, that is, TET2 E03.11 (#17, center 7, 1937 reverse reads), TET2 E11.02 (#15, center 9, 3580 forward reads) and TET2 E11.02 (#15, center 9, 2340 reverse reads), were omitted as outliers from the box-and-whisker plots in Figure 1b due to high coverage.
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PCR setup or amplicon pooling. In the remainder series of six low-level variants, at least one laboratory (range 1-5) had failed to detect the variant with 41% mutation load in at least one sequencing direction and thus was filtered out. As such, more detailed analyses are required to investigate what number of sequencing reads would be minimally required in order to call low-level variants. More detailed information and all raw values are given in Supplementary Data Spreadsheet 2 along with considerations on a minimal coverage in Supplementary Table 5 . Similar to Figure 4b , Bland-Altman analyses of all 14 lowlevel variants o20% were performed to investigate whether systematic differences in the percentages of reads detecting a variant existed (Supplementary Figure 7) . The standard deviations of the low-level variants' relative frequencies were comparable to those of the most likely variants. Hence, the coefficient of variation increases for low-level variances (Supplementary Figure 8) . Generally, further research will be necessary to fully understand the relevance and clinical significance of these small sub-clones. It can be speculated that mutations observed with deep sequencing, but not with conventional Sanger sequencing, are likely to be sub-clonal events with yet unclear biological meaning and clinical impact.
Discussion
Massively parallel pyrosequencing in picoliter-sized wells is an innovative NGS technique that enables a highly-sensitive deep sequencing approach to detect molecular aberrations. 13 However, thus far, limited data are available concerning the technical performance and reproducibility of NGS in the clinical laboratory setting.
Here, we demonstrated the robustness, precision and reproducibility of 454 amplicon deep sequencing across 10 laboratories in 8 countries. Our data further illustrated that expertise in amplicon deep sequencing or applying an automated amplicon purification process is advantageous, but not necessarily required for getting reliable results. We showed that although for individual amplicons the coverage was highly different between the participating centers, the mutational burden in the detected variants was remarkably comparable. As the performance difference detected in the type of molecular barcode used were small, this assay allowed multiplexing of several patient samples per sequencing lane in a multi-gasket format PTP. Therefore, we recognize the utility of amplicon deep sequencing in a diagnostic setting, where multiple genes or hotspot regions thereof are sequenced in multiple patients in a massively parallel way.
From the perspective of routine diagnostics operations, we would thus propose the following consensus recommendations for amplicon deep sequencing. Principally, there are three parts necessary for a successful sequencing result: (i) library preparation, (ii) coverage considerations and (iii) data analysis and result interpretation. We found that isolating the genomic DNA from about five million mononuclear target cells after Ficoll enrichment gives sufficient DNA in high quality for sequencing analysis. In this study, 40 ng per PCR assay were used in order to provide standardized assay conditions. However, we found it feasible to also omit the step of DNA dilution to a certain concentration (data not shown). The same applies to the quantitation of individual PCR products, that is, after repeatedly generating data from the same PCR setup, one can use constant volume estimates instead of fixed input amounts after quantitation of individual reactions. However, it still remains absolutely necessary to quantify final pool libraries as accurately as possible, as these concentrations will be the basis for a final dilution of single DNA molecules to be added to the emulsion PCR step. With respect to emulsion PCR and subsequent assay steps, we found it helpful to separate forward (A bead) and reverse (B bead) reactions in the small volume Titanium setup. Because we chose to separate one PTP into eight distinct lanes, the beads we obtained using the small volume assay format after enrichment were usually sufficient in numbers to load up to 340 000 beads per PTP lane. Importantly, after repeating the same libraries multiple times, one can also expect stable copyper-bead ratios that will yield enrichment ratios, ideally ranging between 8 and 15%, thus carefully titrated ratios for forward and reverse reactions will remain stable over time.
Second, we demonstrated that initial expectations on sequencing coverage could be successfully met. In our setup, we aimed for a 500-fold coverage per amplicon, that is, across 31 amplicons and three patients per lane, at least 46 500 reads would be necessary on an 8-lane PTP to yield ideal and homogeneous results. We thus achieved reliable and reproducible results regarding deep sequencing of TET2, CBL and KRAS analyzing three patients per lane, resulting in a median coverage of more than 500 reads. Further, in this study, a unidirectional coverage of 250-fold was sufficient to detect all variants with a median relative frequency X3%. However, one can easily adjust the coverage settings in experiments in which deeper coverage is required, for example, allowing monitoring for minimal residual disease or identifying low-level variants that might confer resistance to targeted therapies. Therefore, we foresee a scenario where this assay can be applied to monitor for low-level molecular mutations in a tyrosine kinase domain used for targeted treatment (BCR-ABL) or in the case of chronic lymphocytic leukemia to identify small clones harboring TP53 Center Robustness of next-generation amplicon deep sequencing A Kohlmann et al mutations, as such patients might be considered for alternative treatment approaches. [20] [21] [22] Moreover, we recently presented data that ultra-deep resequencing for RUNX1 mutations is feasible and enabled an individualized approach to a patient's disease by monitoring specific mutations in the setting of minimal residual disease. 23 However, it remains to be further investigated what an ideal coverage would be in a diagnostic and clinical setting, and we here attempted to formulate consensus guidelines, in particular, with respect to the heterogeneity of tumor specimens. We are confident that technological advances, such as amplicon deep sequencing, now provide an unbiased means to detect and quantitatively monitor these aberrations during the course of treatment. This might be of particular interest when multiple separate subclones are evident in a specimen and when their composition is changing over time.
Generally, given the total assay run time of approximately 4 days, it is possible to meet a diagnostic requirement of fast turn-around time, not only for candidate gene resequencing in cancer, but also for other applications such as human leukocyte Robustness of next-generation amplicon deep sequencing A Kohlmann et al antigen genotyping at high resolution or identifying drugresistant viral variants. 9, 24 In addition, we recently reported that such a technique is applicable to all PCR products. Grossmann et al. 25 published a study where this assay was applied to sequence CEBPA, a gene with high GC content. Using a modified PCR setup, amplicons with up to 77% GC content were successfully processed by deep sequencing. Moreover, miniaturization and automation of certain assay steps will allow a reasonable bundling of multiple markers per patient, 4, 5 such that high-throughput laboratories will be in a position of offering panels of genes for an individualized approach to diagnose and monitor a patient's disease. For each comparison, the mean of the two relative variant frequencies from a single patient sample at the two centers (x axis) is plotted against the difference between the same two results (y axis). The solid red horizontal line represents the overall mean of the differences and the dashed red lines show the range containing the mean of the differences ± 1.96 standard deviation, which is referred to as the limits of agreement. Depicted in each plot are the data for the 80 most likely variants as listed in Supplementary Table S1 . At most, two variants had to be excluded because of rare amplicon dropouts in one of the two centers included in the comparison.
Finally, the current data analysis pipeline makes it necessary to combine several analysis workflows into an integrated result: (a) using the onboard sequencing instrument image processing algorithms, obtained raw data were processed and the generated reads were aligned against the reference genome; (b) a specific tool for interpretation of amplicon coverage and read distribution was helpful in estimating the overall quality of a sequencing run; 15 and (c) those alignments were then compared against public databases to allow for interpreting SNPs versus true variants. We found that these three distinctive steps were necessary, yet no single software providing all algorithms in a single package was currently available.
In conclusion, our findings from a multicenter analysis have demonstrated that amplicon-based deep sequencing is technically feasible, achieves a high concordance across multiple laboratories and allows a broad and in-depth molecular characterization of hematological malignancies with high diagnostic sensitivity. Moreover, as an international consortium, it was also our intent to provide expert guidance on this deepsequencing application for implementation in routine diagnostic operations. Although many facets of this assay need to be taken into account, for example, the preparation of sequencing libraries with molecular barcodes, specific experimental design options when considering sequencing coverage to calculate diagnostic sensitivity, or the use of suitable software and data processing solutions to obtain accurate results, amplicon deep sequencing has already demonstrated promising technical performance that warrants further development towards routine application of this technology in diagnostic laboratories so that an impact on clinical practice can be achieved.
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